The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Within-Trial Cost-Effectiveness of Lifestyle Intervention or Metformin for the Primary Prevention of Type 2 Diabetes
Open accessAbstract
OBJECTIVE—The Diabetes Prevention Program (DPP) demonstrated that intensive lifestyle and metformin interventions reduced the incidence of type 2 diabetes compared with a placebo intervention. The aim of this study was to assess the cost-effectiveness of the lifestyle and metformin interventions relative to the placebo intervention. RESEARCH DESIGN AND METHODS—Analyses were performed from a health system perspective that considered direct medical costs only and a societal perspective that considered direct medical costs, direct nonmedical costs, and indirect costs. Analyses were performed with the interventions as implemented in the DPP and as they might be implemented in clinical practice. RESULTS—The lifestyle and metformin interventions required more resources than the placebo intervention from a health system perspective, and over 3 years they cost approximately $2,250 more per participant. As implemented in the DPP and from a societal perspective, the lifestyle and metformin interventions cost $24,400 and $34,500, respectively, per case of diabetes delayed or prevented and $51,600 and $99,200 per quality-adjusted life-year (QALY) gained. As the interventions might be implemented in routine clinical practice and from a societal perspective, the lifestyle and metformin interventions cost $13,200 and $14,300, respectively, per case of diabetes delayed or prevented and $27,100 and $35,000 per QALY gained. From a health system perspective, costs per case of diabetes delayed or prevented and costs per QALY gained tended to be lower. CONCLUSIONS—Over 3 years, the lifestyle and metformin interventions were effective and were cost-effective from the perspective of a health system and society. Both interventions are likely to be affordable in routine clinical practice, especially if implemented in a group format and with generic medication pricing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Self-citationTuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Pan, X.-R., Li, G.-W., Hu, Y.-H., Wang, J.-X., Yang, W.-Y., An, Z.-X., Hu, Z.-X., Juan-Lin, Xiao, J.-Z., Cao, H.-B., et al. (1997) · Diabetes Care · doi:10.2337/diacare.20.4.537 · Cited by 4,320
Laupacis, A., Feeny, D. H., Detsky, A. S., & Tugwell, P. (1992) · Europe PMC (PubMed Central) · Cited by 1,581
Five‐Hundred Life‐Saving Interventions and Their Cost‐Effectiveness
Tengs, T. O., Adams, M. E., Pliskin, J. S., Safran, D. G., Siegel, J. E., Weinstein, M. C., & Graham, J. D. (1995) · Risk Analysis · doi:10.1111/j.1539-6924.1995.tb00330.x · Cited by 1,321
The CDC Diabetes Cost-effectiveness Group (2002) · JAMA · doi:10.1001/jama.287.19.2542 · Cited by 508
Health care expenditures for people with diabetes mellitus, 1992.
Rubin, R. J., Altman, W. M., & Mendelson, D. N. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.78.4.8157701 · Cited by 378
The Diabetes Prevention Program Research Group (2003) · Diabetes Care · doi:10.2337/diacare.26.1.36 · Cited by 358
Renjilian, D. A., Perri, M. G., Nezu, A. M., McKelvey, W. F., Shermer, R. L., & Anton, S. D. (2001) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.69.4.717 · Cited by 327
The Cost to Health Plans of Poor Glycemic Control
Gilmer, T. P., O'Connor, P. J., Manning, W. G., & Rush, W. A. (1997) · Diabetes Care · doi:10.2337/diacare.20.12.1847 · Cited by 304
Kaplan, R. M., Atkins, C. J., & Timms, R. (1984) · Journal of Chronic Diseases · doi:10.1016/0021-9681(84)90050-x · Cited by 301
A Comprehensive League Table of Cost-Utility Ratios and a Sub-table of "Panel-worthy" Studies
Chapman, R. H., Stone, P. W., Sandberg, E. A., Bell, C., & Neumann, P. J. (2000) · Medical Decision Making · doi:10.1177/0272989x0002000409 · Cited by 165
The quality of well-being scale: critical similarities and differences with SF-36
Kaplan, R., Ganiats, T., Sieber, W., & Anderson, J. (1998) · International Journal for Quality in Health Care · doi:10.1093/intqhc/10.6.509 · Cited by 158
Kaplan, R. M., Hartwell, S. L., Wilson, D. K., & Wallace, J. P. (1987) · Journal of General Internal Medicine · doi:10.1007/bf02596443 · Cited by 145
Wadden, T. A., Foster, G. L., Letizia, K. A., & Stunkard, A. J. (1992) · Archives of Internal Medicine · doi:10.1001/archinte.1992.00400170051010 · Cited by 133
Type 2 diabetes: incremental medical care costs during the first 8 years after diagnosis.
Brown, J. B., Nichols, G. A., Glauber, H. S., & Bakst, A. W. (1999) · Diabetes Care · doi:10.2337/diacare.22.7.1116 · Cited by 124
Interday Reliability of Function Assessment for a Health Status Measure
Anderson, J. P., Kaplan, R. M., Berry, C. C., Bush, J. W., & Rumbaut, R. G. (1989) · Medical Care · doi:10.1097/00005650-198911000-00008 · Cited by 122
Behavior therapy for obesity: A comparative investigation of long-term efficacy.
Kingsley, R. G., & Wilson, G. T. (1977) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.45.2.288 · Cited by 122
Quality of life assessment for cost/utility studies in cancer
Kaplan, R. M. (1993) · Cancer Treatment Reviews · doi:10.1016/0305-7372(93)90061-u · Cited by 77
Value Judgment in the Oregon Medicaid Experiment
Kaplan, R. M. (1994) · Medical Care · doi:10.1097/00005650-199410000-00001 · Cited by 59
Economic Analyses of Diabetes Interventions
Herman, W. H. (1999) · The Endocrinologist · doi:10.1097/00019616-199903000-00008 · Cited by 9
Cited by
International Diabetes Federation: a consensus on Type 2 diabetes prevention
Alberti, K. G. M. M., Zimmet, P., & Shaw, J. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02157.x · Cited by 778
Herman, W. H., Hoerger, T. J., Brandle, M., Hicks, K., Sorensen, S., Zhang, P., Hamman, R. F., Ackermann, R. T., Engelgau, M. M., Ratner, R. E., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-5-200503010-00007 · Cited by 703
Priorities Among Effective Clinical Preventive Services
Maciosek, M. V., Coffield, A. B., Edwards, N. M., Flottemesch, T. J., Goodman, M. J., & Solberg, L. I. (2006) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2006.03.012 · Cited by 625
Cost-Effectiveness of Interventions to Prevent and Control Diabetes Mellitus: A Systematic Review
Li, R., Zhang, P., Barker, L. E., Chowdhury, F. M., & Zhang, X. (2010) · Diabetes Care · doi:10.2337/dc10-0843 · Cited by 491
The 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention
The Diabetes Prevention Program Research Group (2012) · Diabetes Care · doi:10.2337/dc11-1468 · Cited by 436
Metadata
- Authors
- Diabetes Prevention Program Research Group
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2003-09-01
- Volume
- 26
- Issue
- 9
- Pages
- 2518-2523
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4210751332
- Cited by
- 262
- References
- 21
- FWCI
- 30.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.